Trilostane Vs Other Endocrine Meds in Dogs

Trilostane is the medication most pet parents hear about when a dog is diagnosed with Cushing’s disease, also called hyperadrenocorticism. In the United States, Vetoryl is the FDA-approved trilostane product for dogs, and it is approved for both pituitary-dependent and adrenal-dependent Cushing’s disease. That matters because many endocrine drugs in dogs are condition-specific. Levothyroxine is used for hypothyroidism, insulin is used for diabetes mellitus, and desoxycorticosterone pivalate or fludrocortisone are used for Addison’s disease. They are not interchangeable, even though they all affect hormones.

When people compare trilostane with “other endocrine meds,” the most useful comparison is usually trilostane versus mitotane for Cushing’s disease. Selegiline may also come up, but it is approved only for certain uncomplicated pituitary-dependent cases and is used far less often in general practice. Trilostane works by reducing cortisol production rather than destroying adrenal tissue. Mitotane, by contrast, damages part of the adrenal cortex to lower cortisol output. That difference shapes how each drug is monitored, what side effects your vet watches for, and which dogs may be better candidates for one option over another.

For many dogs, trilostane is the standard first-line medical option because it can improve common Cushing’s signs such as increased thirst, increased urination, panting, pot-bellied appearance, skin thinning, and muscle loss. It does not cure the underlying tumor, but it can help control the hormone imbalance and improve day-to-day comfort. Cornell notes that medical therapy with trilostane or mitotane can provide average survival times around 2 to 2.5 years, although individual outcomes vary with the dog’s age, tumor type, other diseases, and how well monitoring is maintained.

The key point for pet parents is that endocrine medications are long-term management tools, not one-size-fits-all solutions. Your vet chooses among them based on the exact diagnosis, lab results, concurrent disease, and your dog’s response over time. In many cases, the best plan is not the most intensive one. It is the one that safely matches your dog’s needs, your monitoring ability, and your household budget.

Trilostane blocks an enzyme involved in adrenal steroid production, which lowers cortisol synthesis. In practical terms, that means it reduces the excess cortisol driving Cushing’s signs. Because it suppresses hormone production rather than permanently destroying adrenal tissue, its effects can be adjusted by changing the dose or stopping the medication if needed. This is one reason many vets prefer it as a starting option for canine Cushing’s disease.

Mitotane works differently. It selectively damages the cortisol-producing layers of the adrenal cortex. That can be effective, but it is less reversible and can push some dogs into hypoadrenocorticism if suppression becomes too strong. Selegiline works at the pituitary level through dopamine pathways and is only approved for certain uncomplicated pituitary-dependent cases. In real-world practice, it is used much less often than trilostane because response rates are less predictable.

Comparing trilostane with other endocrine medications outside Cushing’s disease also helps clarify its role. Levothyroxine replaces missing thyroid hormone in dogs with hypothyroidism. It is a hormone replacement drug, not a suppressive drug. Insulin replaces or supplements insulin activity in diabetes. Desoxycorticosterone pivalate and fludrocortisone replace mineralocorticoid support in Addison’s disease, often alongside glucocorticoids. So while these are all endocrine medications, they solve very different hormone problems.

Trilostane usually starts affecting cortisol production within a day or two, but clinical improvement is monitored over time. Your vet will look at both symptoms and bloodwork because a dog can seem better while still needing dose adjustment, or seem tired because the dose is too strong. That is why endocrine treatment is never only about the prescription. It is about the prescription plus follow-up testing and symptom tracking.

The most common side effects reported with trilostane are reduced appetite, vomiting, diarrhea, low energy, and weakness. Some dogs show mild stomach upset early in treatment, while others develop more serious problems if cortisol drops too low. FDA and VCA both note that severe reactions can include collapse, bloody diarrhea, dangerous sodium and potassium changes, and adrenal injury. These are not routine, but they are important enough that pet parents should know the warning signs.

Compared with mitotane, trilostane is often viewed as easier to titrate, but it still requires close monitoring. Both drugs can cause signs that look like Addison’s disease if cortisol suppression becomes excessive. Dogs that become very weak, stop eating, vomit repeatedly, have diarrhea, tremble, or collapse need urgent veterinary care. See your vet immediately if those signs appear, especially soon after starting the medication or after a dose change.

Side effects also matter when comparing trilostane with other endocrine medications. Levothyroxine side effects are usually related to over-supplementation and may include restlessness, panting, increased heart rate, or increased thirst and urination. Insulin risks center on hypoglycemia. Addison’s medications can affect electrolytes and hydration. In other words, every endocrine drug has its own safety profile, and the “best” medication depends on the disease being treated and the dog’s other health conditions.

One more practical point: trilostane should be handled carefully. Capsules should not be split or opened, and people who are pregnant or trying to conceive should avoid direct exposure. If your dog has kidney disease, liver disease, or takes certain heart medications, your vet may recommend a different plan or more intensive monitoring because the safety margin can be narrower.

Trilostane dosing is individualized. Merck lists a recommended starting dosage range of 2 to 10 mg/kg by mouth every 24 hours, with later increases or decreases based on monitoring results. Many dogs are started conservatively and adjusted over time rather than pushed quickly to a high dose. Your vet may recommend once-daily or divided dosing depending on your dog’s symptom control, lab values, and how long the medication effect seems to last.

This medication is usually given with food, and consistency matters. Give it the same way each day unless your vet tells you otherwise. Monitoring is a core part of dosing. VCA and PetMD note that rechecks are commonly done about 10 to 14 days after starting treatment, again after dose changes, and then at regular intervals once the dog is stable. ACTH stimulation testing is commonly timed a few hours after dosing, though your vet may also use symptom trends, chemistry values, electrolytes, and other cortisol-based strategies depending on the case.

Mitotane dosing is handled very differently because it often involves an induction phase followed by maintenance. That can make the early treatment period feel more intense for some households. Levothyroxine dosing is also individualized, but monitoring focuses on thyroid hormone levels rather than cortisol suppression. These differences are why pet parents should not compare endocrine drugs by capsule count alone. The monitoring schedule is part of the treatment burden and part of the total cost range.

Never change the dose on your own because your dog seems thirstier, calmer, or more tired for a day or two. Endocrine diseases can fluctuate, and symptoms can overlap with side effects. If a dose is missed, ask your vet how to proceed. If your dog is vomiting, refusing food, or acting weak around dosing time, contact your vet before giving the next dose unless you have already been given a specific emergency plan.

Trilostane can interact with medications that affect potassium balance, blood pressure, or adrenal function. FDA warns that it should not be used in dogs with kidney or liver disease and should be used carefully in dogs taking certain heart medications. Product information and veterinary references also caution about combining trilostane with ACE inhibitors or potassium-sparing diuretics because both trilostane and those drugs can influence aldosterone-related electrolyte balance.

That interaction risk is especially important in older dogs, since Cushing’s patients may also have heart disease, kidney changes, or high blood pressure. A dog taking benazepril, enalapril, spironolactone, or similar medications may still be able to use trilostane, but your vet may recommend closer electrolyte checks and slower dose adjustments. This is one of the clearest examples of why endocrine treatment plans need to be individualized.

Other endocrine medications have their own interaction patterns. Levothyroxine can interact with antacids, iron, sucralfate, phenobarbital, corticosteroids, and diabetic medications. That means a dog with more than one endocrine problem may need a carefully staged plan rather than starting everything at once. If your dog has diabetes and Cushing’s disease together, for example, insulin needs may change as cortisol control improves.

Bring your vet a full medication list at every recheck, including supplements, joint products, skin products, and compounded medications. Compounded trilostane may be used in select situations, but PetMD notes that certain compounded formulations may not be as effective as the FDA-approved product. That can complicate interpretation of both symptom control and lab results.